A Study of Fluconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems

Last updated: June 23, 2005
Sponsor: Pfizer
Overall Status: Completed

Phase

3

Condition

Fungal Infections

Systemic Fungal Infections

Vaginal Infection

Treatment

N/A

Clinical Study ID

NCT00002339
120
R-0220
  • Ages 13-70
  • All Genders

Study Summary

To determine the safety, toleration, and efficacy of fluconazole oral suspension in the treatment of esophageal candidiasis in immunocompromised patients, including those with AIDS.

Eligibility Criteria

Inclusion

Inclusion Criteria

Patients must have:

  • AIDS or other immunocompromising condition.

  • Candidal esophagitis.

  • Life expectancy of at least 2 months.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

  • Evidence of non-candidal systemic fungal infection.

  • Abnormalities that may preclude esophagoscopy or endoscopy.

  • Unable to tolerate fluconazole.

  • Unable to give informed consent.

  • Enrollment in other experimental trials of approved or non-approved drugs or systemic compounds (unless approved by the Pfizer Clinical Monitor).

  • Other condition that would make patient unsuitable for enrollment.

Concurrent Medication:

Excluded:

  • Concomitant oral or topical antifungal agent.

  • Other experimental medications.

Patients with the following prior condition are excluded:

History of allergy to imidazoles or azoles.

Prior Medication:

Excluded:

  • Any oral or topical antifungal therapy within the past 3 days. Active use of illicit or illegal drugs.

Study Design

Total Participants: 100
Study Start date:
Estimated Completion Date:

Study Description

Patients receive fluconazole oral suspension for a minimum of 3 weeks and maximum of 8 weeks. Patients are evaluated weekly, and treatment continues for 2 weeks after resolution of symptoms. Endoscopic exams and possibly biopsies are performed at baseline and at the end of treatment. Patients undergo follow-up at 2 weeks post-treatment.

Connect with a study center

  • Los Angeles County - USC Med Ctr

    Los Angeles, California 90033
    United States

    Site Not Available

  • Houston Veterans Administration Med Ctr

    Houston, Texas 77030
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.